Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 1997

View Archived Issues

Oral and nasal sumatriptan studied for migraine

Clinical results presented for Knoll's PEG-hirudin

Clinical pharmacokinetics and safety reported for Sankyo's MAO-A inhibitor

Clinical pharmacokinetics and bradycardic activity of S-16257

Pentoxifylline demonstrates gastroprotective effects in patient study

First combination anti-HIV drug approved in U.S.

Symphony discloses AMPA antagonists

Inhibitors of sCD23 production developed at SmithKline Beecham

Zeneca presents new antibacterials active against resistant pathogens

Na+/K+-exchange inhibitors from Fujisawa

Rhone-Poulenc Rorer discloses new AMPA/NMDA receptor antagonists

Antiviral thienoxazinones prepared at SKB

LY-333334: new bone anabolic agent from Lilly

PathoGenesis presents new antimycobacterial agents

Alza to market IVAX urology products in U.S., Canada

Intron A/ribavirin combination for HCV: preliminary phase III results

Seroquel cleared for marketing in U.S.

Amgen to emphasize calcimimetics program; preliminary phase II results reported for R-568

LF-08-0299 both prevents and reverses kidney rejection in dogs

Patient recruitment for verteporfin phase III trials exceeds goals

New class of antifungal agents developed at Glaxo Wellcome

SNX-111 study in head trauma resumed

Bayer evaluates novel heteroaryl oxazolidinones

Pfizer seeks U.S. and European approval for Viagra

Techniclone submits IND for malignant glioma

Clinical results on neuraminidase inhibitor presented at ICAAC

Inex seeks Canadian approval to commence Onco TCS trials for lymphoma

Warner-Lambert reports dihydropyrone HIV protease inhibitors

Canadian regulatory review of modafinil continues

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026